Building Award-Winning Triple-Bottom-Line Leadership and Innovation for Sustainability

Susanne Stormer@SusStormerVice President, Corporate Sustainability

Novo Nordisk

Building Award-Winning Triple Bottom Line

Leadership and Innovation for Sustainability

Susanne StormerVice President of Corporate Sustainability

Novo Nordisk

1

We can’t prove that Triple Bottom Line thinking is reflected in market value, but it’s hard to argue that it isn’t

Causality or coincidence?

Note: Novo Nordisk market cap for A+B stocks. Data supplied by Investor Relations (Last date 04-02-2016)

0

200

400

600

800

1000

1200

BDKK

2004

2005

2001South African

court case

2008Diversity aspiration

and global standardsfor employee health

2010Climate target

achieved

2014

2005-2009

Oil for Food and business ethics

2000 2002 2004 2006 2008 2010 2011 2012 2014 2016

2015Sustainable Development

Goals

Our philosophy is that corporate social responsibility is nothing but maximizing the value of your company over a long period of time, because in the long term, social and environmental issues become financial issues.

Lars Rebien Sørensen, CEOin Harvard Business Review, November 2015

We believe that a healthy environment, society and economy are fundamental to long-term business success

“I’m leading a team that is collectively creating one of the world’s best-performing companies.”

The Triple Bottom Line is the foundation for how Novo Nordisk creates value and stays successful

Novo Nordisk Way The Triple Bottom Line Articles of Association

2. Objects

The Company’s objects are to carry out research and development and to manufacture and commercialisepharmaceutical, medical and technical products and services as well as any other activity related thereto as determined by the Board of Directors.

The Company strives to conduct its activities in a financially, environmentally, and socially responsible way.

The corporate strategy sets the long-term direction to live up to the commitments in the Novo Nordisk Way

Our ambition is to strengthen our leadership in diabetes.

We aspire to change possibilities in haemophilia and other serious chronic conditions.

Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.

Stakeholders Governance

Aspirations & goals

Integrated thinking in key business

processes Performance

Articles of AssociationNovo Nordisk Way

Strategy and policiesBoards and Committee

Annual strategy review by the Board of Directors

Strategic long-term targets and 2020 aspirations

Specific short-term targets

Trend spottingStakeholder engagementPartnerships

Balanced ScorecardPersonal performance goalsLong-term incentive programmeQuarterly management reportingAnnual reporting

Integrated thinking provides a broader mind-set, strengthens internal collaboration and drives performance

We focus on how we create, capture and communicate value to society and value to the business

DEMONSTRATE RESPONSIBILITY FOR IMPACTS ON SOCIETY

LEAD TOWARDS

PROSPERITY

INTEGRATE SOCIAL AND ENVIRONMENTAL

PRIORITIES IN BUSINESS STRATEGY

Our aspiration is to become a sustainable business and to be a contribution to the future we want

8

The Triple Bottom Line will make us fit to be in business for the next generations

For more information:novonordisk.com/sustainability twitter.com/novonordiskTBL

The Apis bull logo is a registered trademark of Novo Nordisk A/S